Consistent with these studies, we investigated the impact of mammary-epithelial deletion of Cpt1a in an ErbB2 GEMM, revealing a significant delay in tumor onset and reduced metastatic capacity (Fig. 1 and Supplementary Fig. 1). Here, ERBB2 is linked to neoplasm.